Giants of Cancer Care® Program Inductees

Translational Science

Fabrice André, MD, PhD

Head, Research Division, professor, Department of Medical Oncology
Institut Gustave Roussy
Professor, medicine
University of Paris-Saclay

André is the 2024-2025 president-elect of ESMO.
He was the editor-in-chief of Annals of Oncology from 2017 to 2023.
He is a former chair of the ESMO Translational Research and Precision Medicine Working Group.
André is the head and director of the Mixed Research Unit (Inserm 981) “Molecular Predictors and New Targets in Oncology” research unit at Gustave Roussy. In his role, he specializes in the molecular characterization of breast and gynecologic cancers.
He led research on the genomic characterization of metastatic breast cancers, which showed that the driver genes TP53, NF1, ESR1, RIC8A, GATA3, RB1, KMT2C, AKT1, and NCOR1 were more frequently mutated in HR-positive metastatic breast cancers. Furthermore, investigators found that mutations in RB1, TP53, and NF1 were associated with poor disease outcomes.
He served as the lead investigator of the phase 3 SOLAR-1 trial (NCT02437318) in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer, which showed that alpelisib (Piqray) plus fulvestrant (Faslodex) prolonged progression-free survival vs placebo plus fulvestrant in patients who had received prior endocrine therapy.

Home

)

SUPPORTED BY